We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Follow-on investment, led by Epidarex Capital, closes at £4.24m, following initial £3.2m Seed round in 2020; Caribou Property joins as new investor Management appointments expand leadership team: Dr... Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring immune tolerance to treat and potentially cure autoimmune diseases Initi...
Macomics, the Macrophage-based Drug Discovery company, secures £4.24m expansion financing, and appoints CEO, CSO and VP Immunology
Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$48 Million) in this Round